Goal-Directed Strategic Approach Using New Therapies to Reduce Kidney and Cardiovascular Risks in Patients with Diabetic Kidney Disease
Led by Sunnybrook Health Sciences Centre · Updated on 2026-09-04
100
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the feasibility, safety, and implementation of an early goal-directed Cardio-Kidney-Metabolic CKM care strategy compared with usual care in adults living with type 2 diabetes and diabetic kidney disease who are at increased cardiovascular risk. This pilot randomized controlled trial aims to assess whether a structured approach integrating kidney, cardiovascular, and metabolic risk management can be safely and effectively implemented within routine nephrology practice, informing a future larger trial.
Participants will be randomly assigned to one of two groups one receiving a nephrologist-led CKM care strategy involving risk assessments, shared decision-making, guideline-directed medical therapies including RASi, SGLT2i, nsMRA, and GLP-1 RA, and ongoing safety monitoring the other receiving standard nephrology care based on usual clinical practice and clinician judgment. The study follows participants for 12 months, monitoring treatment uptake, adherence, and safety outcomes.
During the study, participants will have regular assessments to evaluate recruitment, retention, treatment implementation, and safety. Researchers will collect data on medication adherence, cardiovascular and kidney-related health measures such as blood pressure, urine albumin-to-creatinine ratio, and estimated glomerular filtration rate, hospitalizations, and mortality. This comprehensive follow-up aims to inform the design of a future definitive trial, with total participation lasting about one year.
CONDITIONS
Brief Title
Goal-Directed Therapy to Reduce Kidney and Cardiovascular Risk in Diabetic Kidney Disease (GOLD-STANDARD)
Research Team
A
Ayodele Odutayo, Doctor
G
GOLD STANDARD Coordinating Centre
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Chronic kidney disease with eGFR between 25 and 60 mL/min/1.73 m² or urine albumin-to-creatinine ratio of 30 mg/g or higher
High cardiovascular risk defined by prior heart attack, stroke, peripheral artery disease, or cardiovascular risk factors including age 40 or older plus high cholesterol, hypertension, or atrial fibrillation
Willingness to start new medications
You will not qualify if you...
Diagnosis of type 1 diabetes
HbA1c level 10% or higher within the past 12 months
Serum potassium level 5.2 mmol/L or higher on screening labs
Baseline blood pressure lower than 100/60 mmHg at screening
Recent treatment with new or intensified immunosuppressive therapy for kidney disease within the last 60 days
History of kidney transplant
Currently treated with maximum tolerated doses of three or more medication classes including RASi, SGLT2i, nsMRA, or GLP1RA
Currently prescribed all four medication classes: RASi, SGLT2i, nsMRA, and GLP1RA
Allergy or intolerance to any of RASi, SGLT2i, nsMRA, or GLP1RA
Known heart failure with reduced ejection fraction
Current pregnancy, breastfeeding, or women of childbearing potential not using highly effective contraception
Your Study Journey
Screening
Duration - Up to 60 days
Participants are screened for eligibility to participate in the trial.
Screening and enrollment visit
Treatment
Duration - 12 months
Participants receive either the goal-directed Cardio-Kidney-Metabolic care led by a nephrologist or standard nephrology care based on clinical judgment. Treatment includes medication management and ongoing safety monitoring.
Regular follow-up visits during the 12 months
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Similar Trials
Randomized Trial Comparing Physical Therapy During Versus Before Hemodialysis in Adults With End-Stage Renal Disease
Natural History Study of Metabolic Rate, Body Composition, and Body Surface Area in Health and Disease
Phase 1b Trial of QX1206 Drug for Adults With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
Evaluating Safety and Effects of Single Dose UBT38006 Injection Compared to Insulin Controls in Healthy Adult Men with Type 2 Diabetes Risk
Phase III Study of HRS-1780 Tablets for Adults With Chronic Kidney Disease to Slow Kidney Function Decline
Evaluating Safety and Effectiveness of Pulse Electric Field Ablation in Adults with Type 2 Diabetes and Poor Blood Sugar Control
A Multicenter Observational Registry on Treatment and Outcomes in Chinese Adults with Chronic Kidney Disease
A Large-Scale Observational Study on Chronic Kidney Disease and Related Risk Factors in China
Study of Weekly NNC0519-0130 Injections Compared to Semaglutide and Placebo for Kidney Health in Adults with Chronic Kidney Disease and Overweight or Obesity
Study of Semaglutide Treatment Effects on Kidney and Heart Health in Adults with Type 2 Diabetes and Chronic Kidney Disease in China
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Brendon L Neuen, Robert A Fletcher, Lauren Heath...
The Effect of Using a Remote Patient Management Platform in Optimizing Guideline-Directed Medical Therapy in Heart Failure Patients: A Randomized Controlled Trial.
Darshan H Brahmbhatt, Heather J Ross, Mary O'Sullivan...
Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE).